Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Wojciech Jurczak, Simon Rule, MD, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD

Blood (2017) 130 (Supplement 1): 2778.

https://doi.org/10.1182/blood.V130.Suppl_1.2778.2778

Published: 2017

Journal Articles

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Dario Marino, MDPhD, Maital Bolshinsky, MD, Silvia Finotto, MD, Raffaele Parrozzani, MD, Caterina Boso, MD, Federica Vianello, MD, Edoardo Midena, MD, Luca Canziani, MD, Laura Evangelista, MD, Vittorina Zagonel, MD

Blood (2017) 130 (Supplement 1): 2781.

https://doi.org/10.1182/blood.V130.Suppl_1.2781.2781

Published: 2017

Journal Articles

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

Carla Casulo, MD, Juan-Manuel Sancho, Koen Van Eygen, MD, Sven de Vos, MD PhD, Santiago Mercadal, MD, Roderick J. Johnson, MD, Kamal Bouabdallah, MD, Houston Holmes, MD FACP, Jan Lemmens, MD, Emmanuel Gyan, MD, Michele Merli, MD, Ranjana H Advani, MD, Lori Steelman, MA, Joseph Pearlberg, MD PhD, Andre Goy, MD

Blood (2016) 128 (22): 2979.

https://doi.org/10.1182/blood.V128.22.2979.2979

Published: 2016

Journal Articles

A Potential Protective Role of Platelets during Septic Shock Does Not Depend on Their Purinergic Receptors

Beatrice Hechler, PhD, Chloé Zimmermann, MSc, Yannick Rabouel, MD, Stéphanie Magnenat, BSc, Mélanie Burban, PhD, Julie Boisramé-Helms, MD PhD, Ferhat Meziani, MD PhD, Christian Gachet, MD PhD

Blood (2016) 128 (22): 2537.

https://doi.org/10.1182/blood.V128.22.2537.2537

Published: 2016

Journal Articles

Thrombophilic Factors in Retinal Vessel Thrombosis: A Single Center Experience

Nicole Maxey, MD, Zeinab Mohammadi, MD, Pamela Dominguez-Perez, MD, Erasto Cortes, MD, Nishaal Antony, MD, Mark M Landeros, MD, Carmen Arango, MD, Angel Campos-Gines, MD, Carlos W Vazquez, MD, Juan Herrada, MD

Blood (2015) 126 (23): 4715.

https://doi.org/10.1182/blood.V126.23.4715.4715

Published: 2015

Journal Articles

Safety & Efficacy of Human Plasma Derived Plasminogen Ophthalmic Drops for Treatment of Ligneous Conjunctivitis: Report of Phase 2/3 Clinical Trial

Charles T Nakar, MD, Roberto Caputo, MD, Francis W Price, Jr., MD, Maria Teresa Sartori, MD, Andrea Leonardi, Anna Lotti Suffredini, Neelam Thukral, Jacopo Secci, Bennie H Jeng, MD, Amy D Shapiro, MD

Blood (2015) 126 (23): 2288.

https://doi.org/10.1182/blood.V126.23.2288.2288

Published: 2015

Journal Articles

In Vitro and in Vivo oncolytic Activity of Lasota Strain of Newcastle Disease Virus on a Lymphoma B-Cell Line and a Canine Cutaneous T-Cell Lymphoma

Diana Sanchez., MVZ (PhDstudent), Rosana Pelayo, PhD, Rosa Elena Sarmiento, PhD, Luis Alberto Medina, PhD, Gabriela N. Cesarman-Maus, MDPhD, Luis Nuñez, MVZ, Nicolle Carrillo, MVZ, Jose de Jesus Paredes, MBA, Hortencia Corona, MS, Eduardo Vadillo, MS

Blood (2014) 124 (21): 5504.

https://doi.org/10.1182/blood.V124.21.5504.5504

Published: 2014

Journal Articles

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Karuna Ganesh, MBBChir, PhD, Connie Batlevi, MD PhD, Zhigang Zhang, PhD, Hani Hassoun, MD, Nikoletta Lendvai, MD PhD, Heather Landau, MD, Craig H. Moskowitz, MD, Philip Caron, MD PhD, Robert Motzer, MD, Sergio A Giralt, MD, Paul Hamlin, MD, Stuart M. Lichtman, MD, Matthew J. Matasar, MD MS, Carol S Portlock, MD, Neerav Shukla, MD, Carol Wasserheit-Lieblich, MD, Andrew D. Zelenetz, MD PhD, John F. Gerecitano, MD PhD

Blood (2014) 124 (21): 3487.

https://doi.org/10.1182/blood.V124.21.3487.3487

Published: 2014

Journal Articles

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Maro Ohanian, DO, Mona Lisa Alattar, MD, Zeev Estrov, MD, PhD, Alfonso Quintas-Cardama, MD, John T Manning, MD, Farhad Ravandi, MD, Lynne V. Abruzzo, MD, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1463.

https://doi.org/10.1182/blood.V120.21.1463.1463

Published: 2012

Journal Articles

Paraneoplastic Pemphigus (PNP) As a Presenting Finding in a Patient with Hodgkin's Lymphoma

Philip Marjon, MD, Byung Kim, MD, Tamara Lazic, MD, Christina Cernik, MD, Ritesh Rathore, MD

Blood (2011) 118 (21): 4864.

https://doi.org/10.1182/blood.V118.21.4864.4864

Published: 2011

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

Blood (2011) 118 (21): 257.

https://doi.org/10.1182/blood.V118.21.257.257

Published: 2011

Journal Articles

Is Standard Treatment (DA 3+7) Is Still Recommended As Front Line Therapy for Adult Patients with De Novo AML? the Role of Etoposide

Firas Al Sabty, MD, PhD, Eva Demeckova, Ladislav Sopko, Eva Weismanova, Martin Mistrik, MD, PhD

Blood (2011) 118 (21): 4272.

https://doi.org/10.1182/blood.V118.21.4272.4272

Published: 2011

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

Blood (2008) 112 (11): 134.

https://doi.org/10.1182/blood.V112.11.134.134

Published: 2008

Journal Articles

Risk Factors and Survival Analyses of Ocular Graft-Versus-Host Disease (GVHD) in the Current Era of Allogeneic Stem Cell Transplant (SCT).

Madan Jagasia, MD, MS, Sunny Mehrotra, Vinita Singh, Adetola A. Kassim, MD, MS, Brian Engelhardt, MD, MS, Sheri Dixon, Uyen Tran

Blood (2008) 112 (11): 2200.

https://doi.org/10.1182/blood.V112.11.2200.2200

Published: 2008

Journal Articles

Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease.

Antonia M.S. Mueller, MD, Jessica A. Allen, BA, David Miklos, MD PhD, Judith A. Shizuru, MD PhD

Blood (2007) 110 (11): 3237.

https://doi.org/10.1182/blood.V110.11.3237.3237

Published: 2007

Journal Articles

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

Mohamad A. Hussein, MD, James R. Berenson, MD, Ruben Niesvizky, MD, Nikhil C. Munshi, MD, Jeffrey Matous, MD, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 3576.

https://doi.org/10.1182/blood.V108.11.3576.3576

Published: 2006

Journal Articles

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

Ranjana Advani, MD, Andres Forero-Torres, MD, Richard R. Furman, MD, Joseph D. Rosenblatt, MD, Anas Younes, MD, Brooke Shankles, MA, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 695.

https://doi.org/10.1182/blood.V108.11.695.695

Published: 2006

Journal Articles

High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial.

Blood (2006) 108 (11): 609.

https://doi.org/10.1182/blood.V108.11.609.609

Published: 2006

Journal Articles

Imatinib Mesylate in the Treatment of Systemic Mastocytosis with Wild-Type c-Kit Codon 816.

Fred H. Hsieh, MD, Alan E. Lichtin, M.D., Hary T. Katz, M.D., Susan Lubell, PA-C, Dorothy Vasas, R.N., Aridth Gibbons, Pankaj Sharma, Ph.D., S.J. Haque, Ph.D.

Blood (2006) 108 (11): 4926.

https://doi.org/10.1182/blood.V108.11.4926.4926

Published: 2006

Journal Articles

High Dose Cytosine Arabinoside (HD-AraC) vs Standard Dose AraC (SD-AraC) during Induction, and Stem Cell Transplantation Followed by IL-2 or No Maintenance in Acute Myelogenous Leukemia (AML): First Report on the AML-12 Phase III Trial of the EORTC-Leukemia Group (LG) and GIMEMA.

Blood (2005) 106 (11): 271.

https://doi.org/10.1182/blood.V106.11.271.271

Published: 2005

NARROW

First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

A Potential Protective Role of Platelets during Septic Shock Does Not Depend on Their Purinergic Receptors

Thrombophilic Factors in Retinal Vessel Thrombosis: A Single Center Experience

Safety & Efficacy of Human Plasma Derived Plasminogen Ophthalmic Drops for Treatment of Ligneous Conjunctivitis: Report of Phase 2/3 Clinical Trial

In Vitro and in Vivo oncolytic Activity of Lasota Strain of Newcastle Disease Virus on a Lymphoma B-Cell Line and a Canine Cutaneous T-Cell Lymphoma

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Paraneoplastic Pemphigus (PNP) As a Presenting Finding in a Patient with Hodgkin's Lymphoma

Is Standard Treatment (DA 3+7) Is Still Recommended As Front Line Therapy for Adult Patients with De Novo AML? the Role of Etoposide

Risk Factors and Survival Analyses of Ocular Graft-Versus-Host Disease (GVHD) in the Current Era of Allogeneic Stem Cell Transplant (SCT).

Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease.

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial.

Imatinib Mesylate in the Treatment of Systemic Mastocytosis with Wild-Type c-Kit Codon 816.

High Dose Cytosine Arabinoside (HD-AraC) vs Standard Dose AraC (SD-AraC) during Induction, and Stem Cell Transplantation Followed by IL-2 or No Maintenance in Acute Myelogenous Leukemia (AML): First Report on the AML-12 Phase III Trial of the EORTC-Leukemia Group (LG) and GIMEMA.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only